- Home
- ENTX vs FLL Comparison
ENTX vs FLL Comparison
Compare ENTX & FLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTX
- FLL
- Stock Information
- Founded
- ENTX 2010
- FLL 1987
- Country
- ENTX Israel
- FLL United States
- Employees
- ENTX N/A
- FLL N/A
- Industry
- ENTX Biotechnology: Biological Products (No Diagnostic Substances)
- FLL Hotels/Resorts
- Sector
- ENTX Health Care
- FLL Consumer Discretionary
- Exchange
- ENTX Nasdaq
- FLL Nasdaq
- Market Cap
- ENTX 101.3M
- FLL 116.4M
- IPO Year
- ENTX 2018
- FLL 1993
- Fundamental
- Price
- ENTX $2.11
- FLL $3.14
- Analyst Decision
- ENTX Strong Buy
- FLL Strong Buy
- Analyst Count
- ENTX 1
- FLL 4
- Target Price
- ENTX $10.00
- FLL $6.00
- AVG Volume (30 Days)
- ENTX 43.0K
- FLL 160.7K
- Earning Date
- ENTX 05-13-2025
- FLL 05-08-2025
- Dividend Yield
- ENTX N/A
- FLL N/A
- EPS Growth
- ENTX N/A
- FLL N/A
- EPS
- ENTX N/A
- FLL N/A
- Revenue
- ENTX $181,000.00
- FLL $297,199,000.00
- Revenue This Year
- ENTX N/A
- FLL $10.53
- Revenue Next Year
- ENTX N/A
- FLL $7.53
- P/E Ratio
- ENTX N/A
- FLL N/A
- Revenue Growth
- ENTX N/A
- FLL 13.92
- 52 Week Low
- ENTX $1.41
- FLL $2.86
- 52 Week High
- ENTX $2.79
- FLL $5.90
- Technical
- Relative Strength Index (RSI)
- ENTX 52.23
- FLL 42.41
- Support Level
- ENTX $2.08
- FLL $3.06
- Resistance Level
- ENTX $2.41
- FLL $3.40
- Average True Range (ATR)
- ENTX 0.19
- FLL 0.26
- MACD
- ENTX -0.00
- FLL 0.05
- Stochastic Oscillator
- ENTX 38.16
- FLL 26.39
About ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.
About FLL Full House Resorts Inc.
Full House Resorts Inc owns, operates, develops, manages, and invests in casinos and related hospitality and entertainment facilities. It offers facilities related to gaming, hotel, dining, entertainment, retail, and other amenities. The group's reportable segments are Midwest & South, West, and Contracted Sports Wagering, It generates the majority of its revenue from the Midwest & South segment which includes Silver Slipper Casino and Hotel, Rising Star Casino Resort, and American Place. The west segment includes Grand Lodge, Stockman's Casino, Bronco Billy's Casino and Hotel, and Chamonix Casino Hotel. The Contracted Sports Wagering segment comprises on-site and online sports wagering skins.